CD Antigen Cancer Therapy Market - Global Outlook and Forecast 2022-2028

January 2022 | 110 pages | ID: C85AE55BE8D8EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of CD Antigen Cancer Therapy in Global, including the following market information:

Global CD Antigen Cancer Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global CD Antigen Cancer Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of CD Antigen Cancer Therapy include GlaxoSmithKline, Celltrion, Pfizer, UCB, Roche, Merck, Johnson & Johnson, Novartis and Eli Lilly, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CD Antigen Cancer Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global CD Antigen Cancer Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global CD Antigen Cancer Therapy Market Segment Percentages, by Type, 2021 (%)

• Intravenous
• Subcutaneous
• Others

Global CD Antigen Cancer Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global CD Antigen Cancer Therapy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Other

Global CD Antigen Cancer Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global CD Antigen Cancer Therapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies CD Antigen Cancer Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies CD Antigen Cancer Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GlaxoSmithKline
• Celltrion
• Pfizer
• UCB
• Roche
• Merck
• Johnson & Johnson
• Novartis
• Eli Lilly
• Bayer
• AstraZeneca
• Spectrum Pharmaceuticals
• Seattle Genetics
• AryoGen Biopharma
• Biogen Idec
• Celltrion
• Hetero Drugs

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 CD Antigen Cancer Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global CD Antigen Cancer Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CD ANTIGEN CANCER THERAPY OVERALL MARKET SIZE

2.1 Global CD Antigen Cancer Therapy Market Size: 2021 VS 2028
2.2 Global CD Antigen Cancer Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top CD Antigen Cancer Therapy Players in Global Market
3.2 Top Global CD Antigen Cancer Therapy Companies Ranked by Revenue
3.3 Global CD Antigen Cancer Therapy Revenue by Companies
3.4 Top 3 and Top 5 CD Antigen Cancer Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies CD Antigen Cancer Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 CD Antigen Cancer Therapy Players in Global Market
  3.6.1 List of Global Tier 1 CD Antigen Cancer Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 CD Antigen Cancer Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global CD Antigen Cancer Therapy Market Size Markets, 2021 & 2028
  4.1.2 Intravenous
  4.1.3 Subcutaneous
  4.1.4 Others
4.2 By Type - Global CD Antigen Cancer Therapy Revenue & Forecasts
  4.2.1 By Type - Global CD Antigen Cancer Therapy Revenue, 2017-2022
  4.2.2 By Type - Global CD Antigen Cancer Therapy Revenue, 2023-2028
  4.2.3 By Type - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global CD Antigen Cancer Therapy Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Other
5.2 By Application - Global CD Antigen Cancer Therapy Revenue & Forecasts
  5.2.1 By Application - Global CD Antigen Cancer Therapy Revenue, 2017-2022
  5.2.2 By Application - Global CD Antigen Cancer Therapy Revenue, 2023-2028
  5.2.3 By Application - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global CD Antigen Cancer Therapy Market Size, 2021 & 2028
6.2 By Region - Global CD Antigen Cancer Therapy Revenue & Forecasts
  6.2.1 By Region - Global CD Antigen Cancer Therapy Revenue, 2017-2022
  6.2.2 By Region - Global CD Antigen Cancer Therapy Revenue, 2023-2028
  6.2.3 By Region - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America CD Antigen Cancer Therapy Revenue, 2017-2028
  6.3.2 US CD Antigen Cancer Therapy Market Size, 2017-2028
  6.3.3 Canada CD Antigen Cancer Therapy Market Size, 2017-2028
  6.3.4 Mexico CD Antigen Cancer Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe CD Antigen Cancer Therapy Revenue, 2017-2028
  6.4.2 Germany CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.3 France CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.4 U.K. CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.5 Italy CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.6 Russia CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries CD Antigen Cancer Therapy Market Size, 2017-2028
  6.4.8 Benelux CD Antigen Cancer Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia CD Antigen Cancer Therapy Revenue, 2017-2028
  6.5.2 China CD Antigen Cancer Therapy Market Size, 2017-2028
  6.5.3 Japan CD Antigen Cancer Therapy Market Size, 2017-2028
  6.5.4 South Korea CD Antigen Cancer Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia CD Antigen Cancer Therapy Market Size, 2017-2028
  6.5.6 India CD Antigen Cancer Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America CD Antigen Cancer Therapy Revenue, 2017-2028
  6.6.2 Brazil CD Antigen Cancer Therapy Market Size, 2017-2028
  6.6.3 Argentina CD Antigen Cancer Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa CD Antigen Cancer Therapy Revenue, 2017-2028
  6.7.2 Turkey CD Antigen Cancer Therapy Market Size, 2017-2028
  6.7.3 Israel CD Antigen Cancer Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia CD Antigen Cancer Therapy Market Size, 2017-2028
  6.7.5 UAE CD Antigen Cancer Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 GlaxoSmithKline
  7.1.1 GlaxoSmithKline Corporate Summary
  7.1.2 GlaxoSmithKline Business Overview
  7.1.3 GlaxoSmithKline CD Antigen Cancer Therapy Major Product Offerings
  7.1.4 GlaxoSmithKline CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.1.5 GlaxoSmithKline Key News
7.2 Celltrion
  7.2.1 Celltrion Corporate Summary
  7.2.2 Celltrion Business Overview
  7.2.3 Celltrion CD Antigen Cancer Therapy Major Product Offerings
  7.2.4 Celltrion CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.2.5 Celltrion Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer CD Antigen Cancer Therapy Major Product Offerings
  7.3.4 Pfizer CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 UCB
  7.4.1 UCB Corporate Summary
  7.4.2 UCB Business Overview
  7.4.3 UCB CD Antigen Cancer Therapy Major Product Offerings
  7.4.4 UCB CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.4.5 UCB Key News
7.5 Roche
  7.5.1 Roche Corporate Summary
  7.5.2 Roche Business Overview
  7.5.3 Roche CD Antigen Cancer Therapy Major Product Offerings
  7.5.4 Roche CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.5.5 Roche Key News
7.6 Merck
  7.6.1 Merck Corporate Summary
  7.6.2 Merck Business Overview
  7.6.3 Merck CD Antigen Cancer Therapy Major Product Offerings
  7.6.4 Merck CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.6.5 Merck Key News
7.7 Johnson & Johnson
  7.7.1 Johnson & Johnson Corporate Summary
  7.7.2 Johnson & Johnson Business Overview
  7.7.3 Johnson & Johnson CD Antigen Cancer Therapy Major Product Offerings
  7.7.4 Johnson & Johnson CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.7.5 Johnson & Johnson Key News
7.8 Novartis
  7.8.1 Novartis Corporate Summary
  7.8.2 Novartis Business Overview
  7.8.3 Novartis CD Antigen Cancer Therapy Major Product Offerings
  7.8.4 Novartis CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.8.5 Novartis Key News
7.9 Eli Lilly
  7.9.1 Eli Lilly Corporate Summary
  7.9.2 Eli Lilly Business Overview
  7.9.3 Eli Lilly CD Antigen Cancer Therapy Major Product Offerings
  7.9.4 Eli Lilly CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.9.5 Eli Lilly Key News
7.10 Bayer
  7.10.1 Bayer Corporate Summary
  7.10.2 Bayer Business Overview
  7.10.3 Bayer CD Antigen Cancer Therapy Major Product Offerings
  7.10.4 Bayer CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.10.5 Bayer Key News
7.11 AstraZeneca
  7.11.1 AstraZeneca Corporate Summary
  7.11.2 AstraZeneca Business Overview
  7.11.3 AstraZeneca CD Antigen Cancer Therapy Major Product Offerings
  7.11.4 AstraZeneca CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.11.5 AstraZeneca Key News
7.12 Spectrum Pharmaceuticals
  7.12.1 Spectrum Pharmaceuticals Corporate Summary
  7.12.2 Spectrum Pharmaceuticals Business Overview
  7.12.3 Spectrum Pharmaceuticals CD Antigen Cancer Therapy Major Product Offerings
  7.12.4 Spectrum Pharmaceuticals CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.12.5 Spectrum Pharmaceuticals Key News
7.13 Seattle Genetics
  7.13.1 Seattle Genetics Corporate Summary
  7.13.2 Seattle Genetics Business Overview
  7.13.3 Seattle Genetics CD Antigen Cancer Therapy Major Product Offerings
  7.13.4 Seattle Genetics CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.13.5 Seattle Genetics Key News
7.14 AryoGen Biopharma
  7.14.1 AryoGen Biopharma Corporate Summary
  7.14.2 AryoGen Biopharma Business Overview
  7.14.3 AryoGen Biopharma CD Antigen Cancer Therapy Major Product Offerings
  7.14.4 AryoGen Biopharma CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.14.5 AryoGen Biopharma Key News
7.15 Biogen Idec
  7.15.1 Biogen Idec Corporate Summary
  7.15.2 Biogen Idec Business Overview
  7.15.3 Biogen Idec CD Antigen Cancer Therapy Major Product Offerings
  7.15.4 Biogen Idec CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.15.5 Biogen Idec Key News
7.16 Celltrion
  7.16.1 Celltrion Corporate Summary
  7.16.2 Celltrion Business Overview
  7.16.3 Celltrion CD Antigen Cancer Therapy Major Product Offerings
  7.16.4 Celltrion CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.16.5 Celltrion Key News
7.17 Hetero Drugs
  7.17.1 Hetero Drugs Corporate Summary
  7.17.2 Hetero Drugs Business Overview
  7.17.3 Hetero Drugs CD Antigen Cancer Therapy Major Product Offerings
  7.17.4 Hetero Drugs CD Antigen Cancer Therapy Revenue in Global Market (2017-2022)
  7.17.5 Hetero Drugs Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. CD Antigen Cancer Therapy Market Opportunities & Trends in Global Market
Table 2. CD Antigen Cancer Therapy Market Drivers in Global Market
Table 3. CD Antigen Cancer Therapy Market Restraints in Global Market
Table 4. Key Players of CD Antigen Cancer Therapy in Global Market
Table 5. Top CD Antigen Cancer Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global CD Antigen Cancer Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global CD Antigen Cancer Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies CD Antigen Cancer Therapy Product Type
Table 9. List of Global Tier 1 CD Antigen Cancer Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CD Antigen Cancer Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global CD Antigen Cancer Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - CD Antigen Cancer Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - CD Antigen Cancer Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global CD Antigen Cancer Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - CD Antigen Cancer Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - CD Antigen Cancer Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global CD Antigen Cancer Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global CD Antigen Cancer Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global CD Antigen Cancer Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America CD Antigen Cancer Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe CD Antigen Cancer Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia CD Antigen Cancer Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America CD Antigen Cancer Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa CD Antigen Cancer Therapy Revenue, (US$, Mn), 2023-2028
Table 30. GlaxoSmithKline Corporate Summary
Table 31. GlaxoSmithKline CD Antigen Cancer Therapy Product Offerings
Table 32. GlaxoSmithKline CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Celltrion Corporate Summary
Table 34. Celltrion CD Antigen Cancer Therapy Product Offerings
Table 35. Celltrion CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer CD Antigen Cancer Therapy Product Offerings
Table 38. Pfizer CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 39. UCB Corporate Summary
Table 40. UCB CD Antigen Cancer Therapy Product Offerings
Table 41. UCB CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Roche Corporate Summary
Table 43. Roche CD Antigen Cancer Therapy Product Offerings
Table 44. Roche CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Merck Corporate Summary
Table 46. Merck CD Antigen Cancer Therapy Product Offerings
Table 47. Merck CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Johnson & Johnson Corporate Summary
Table 49. Johnson & Johnson CD Antigen Cancer Therapy Product Offerings
Table 50. Johnson & Johnson CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Novartis Corporate Summary
Table 52. Novartis CD Antigen Cancer Therapy Product Offerings
Table 53. Novartis CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Eli Lilly Corporate Summary
Table 55. Eli Lilly CD Antigen Cancer Therapy Product Offerings
Table 56. Eli Lilly CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Bayer Corporate Summary
Table 58. Bayer CD Antigen Cancer Therapy Product Offerings
Table 59. Bayer CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 60. AstraZeneca Corporate Summary
Table 61. AstraZeneca CD Antigen Cancer Therapy Product Offerings
Table 62. AstraZeneca CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 63. Spectrum Pharmaceuticals Corporate Summary
Table 64. Spectrum Pharmaceuticals CD Antigen Cancer Therapy Product Offerings
Table 65. Spectrum Pharmaceuticals CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 66. Seattle Genetics Corporate Summary
Table 67. Seattle Genetics CD Antigen Cancer Therapy Product Offerings
Table 68. Seattle Genetics CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 69. AryoGen Biopharma Corporate Summary
Table 70. AryoGen Biopharma CD Antigen Cancer Therapy Product Offerings
Table 71. AryoGen Biopharma CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 72. Biogen Idec Corporate Summary
Table 73. Biogen Idec CD Antigen Cancer Therapy Product Offerings
Table 74. Biogen Idec CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 75. Celltrion Corporate Summary
Table 76. Celltrion CD Antigen Cancer Therapy Product Offerings
Table 77. Celltrion CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)
Table 78. Hetero Drugs Corporate Summary
Table 79. Hetero Drugs CD Antigen Cancer Therapy Product Offerings
Table 80. Hetero Drugs CD Antigen Cancer Therapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. CD Antigen Cancer Therapy Segment by Type in 2021
Figure 2. CD Antigen Cancer Therapy Segment by Application in 2021
Figure 3. Global CD Antigen Cancer Therapy Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global CD Antigen Cancer Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global CD Antigen Cancer Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CD Antigen Cancer Therapy Revenue in 2021
Figure 8. By Type - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 12. US CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 16. Germany CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 24. China CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa CD Antigen Cancer Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE CD Antigen Cancer Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. GlaxoSmithKline CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Celltrion CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. UCB CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Roche CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Johnson & Johnson CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Novartis CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Eli Lilly CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bayer CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. AstraZeneca CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Spectrum Pharmaceuticals CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Seattle Genetics CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. AryoGen Biopharma CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Biogen Idec CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Celltrion CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Hetero Drugs CD Antigen Cancer Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)